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ORIGINAL ARTICLE
Introduction: Clinical outcomes and prognosis of recurrent thy-
moma are not well known because of its rarity and indolent clinical 
course. This study was designed to determine the clinical outcomes 
and prognosis of recurrent thymoma.
Methods: Between 1986 and 2009, 41 of 305 patients who under-
went resection for thymoma had recurrence. We reviewed those 
patients retrospectively.
Results: Of 15 patients who underwent re-resection for recurrent 
thymoma, 13 patients (87%) achieved complete re-resection. Of 26 
patients who did not undergo re-resection, 11 patients received che-
motherapy, five received chemoradiotherapy, one received another 
treatment, and nine patients did not receive any treatment. World 
Health Organization histological types AB or B1 and complete re-
resection were positive prognostic factors. The complete re-resection 
group had better survival after recurrence than the non/incomplete 
re-resection group (5-year survival rate: 90.9% versus 44.7%, p = 
0.014). The complete re-resection group had comparable survival 
after initial resection of thymoma to the patients without recur-
rence (5-year, 10-year survival: 91.7%, 91.7% versus 90.7%, 86.5%, 
p = 0.618) and better survival compared with the non/incomplete 
re-resection group (5-year, 10-year survival: 91.7%, 91.7% versus 
81.6%, 56.7%, p = 0.018).
Conclusions: World Health Organization histologic types AB or 
B1 and complete re-resection are favorable prognostic factors of 
recurrent thymoma. In particular, complete re-resection of recur-
rent thymoma contributes to better survival than other management. 
Therefore, we suggest that long-term surveillance extended at least 
20 years may be essential for early detection of recurrence to increase 
the chance of complete re-resection of recurrent thymoma.
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(J Thorac Oncol. 2012;7: 1304–1314)
Thymoma is rare tumor, accounting for only 0.2% to 1.5% of all malignancies1; however, it is the most common medias-
tinal mass in adults, comprising up to 50% of anterior medias-
tinal masses.2 The recurrence rate of thymoma after resection 
has been reported to be from 5% to 50% according to the ini-
tial stage.3 However, because of the relatively small number of 
recurrences, its late recurrence, and variable pattern of recur-
rence, it is difficult to accurately validate the efficacy of man-
agement. Thus, the management of recurrent thymoma and its 
prognosis are not well known. Only small numbers of studies 
regarding the management of recurrent thymoma have been 
published.3–8 Most published studies recommend re-resection 
for recurrent thymoma when feasible.4–6,9,10 If unresectable, 
chemotherapy is recommended.9–11 However, there is still no 
standard guideline for management of recurrent thymoma. 
Therefore, this retrospective study was designed (1) to detail 
our institutional experience of management for recurrent thy-
moma, (2) to assess the clinical outcomes after management of 
recurrent thymoma, and (3) to analyze the prognosis of recur-
rent thymoma.
PATIENTS AND METHODS
Patients and Definition
The Institutional Review Board of Yonsei University 
College of Medicine approved this retrospective study. The 
need for individual consent of patients whose records were 
evaluated was waived because individuals were not identified 
in the study. Between January 1986 and December 2009, a 
total of 411 consecutive patients underwent surgery for a thy-
mic epithelial tumor at our institute. Of those, we excluded 
patients with an undetermined World Health Organization 
(WHO) histological type (n = 19) because of the unavailabil-
ity of specimen slides or a total infarcted tumor, patients with 
type C thymoma (n = 68), and patients who only underwent an 
open biopsy or R2 resection (n = 19).
Recurrence was diagnosed when thymoma was strongly 
suspected clinically regardless of pathological confirmation 
by biopsy. This definition is based on the recommendation of 
the International Thymic Malignancy Interest Group.12
Of the remaining 305 patients who underwent thymoma 
resection with curative intent, 41 patients (13.4%) had 
recurrences. We reviewed those 41 patients retrospectively. 
The diagram of our study is shown in Figure 1.
Recurrence was divided into three categories accord-
ing to the definition of the International Thymic Malignancy 
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Interest Group.12 A local recurrence was defined as disease 
appearing in the anterior mediastinum or tissues immediately 
contiguous with the resected thymoma (i.e., pleural recurrence 
in the area of a previously resected stage IVa tumor, cervical 
lymph node adjacent to the previously resected thymoma). A 
regional recurrence was defined as intrathoracic recurrence 
that is not contiguous with the thymus or previous resected 
thymoma (i.e., pleural and pericardial nodules). A distant 
recurrence included extrathoracic recurrence and intraparen-
chymal pulmonary nodules.
Histology and Staging
Pathological results were confirmed by an experienced 
pathologist (W.I.Y.) who was blind to the clinical data. The 
thymomas were classified into histological types A, AB, B1, 
B2, and B3 according to the WHO classification system.13 In 
analysis of prognosis, tumors with mixed histologic type were 
classified as the type with the highest malignancy, because 
combined thymomas share similar epidemiologic and clini-
cal features with tumors exhibiting the more malignant his-
tological type,14 and the prognosis of combined thymomas is 
determined mainly by the most malignant component.15 For 
example, when the tumor had both B2 and B3 components, 
the tumor was classified as type B3. Tumor stage was clas-
sified into I, II, III, IVa, or IVb following the Masaoka clas-
sification system16; stage was determined by review of the 
surgical records and pathological reports.
Treatment of Initial Thymoma
Surgery. Extended thymectomy, which was defined as 
the resection of the entire thymus and mediastinal fat tissue 
between both phrenic nerves, was performed in 254 patients 
(83.3%) of 305 patients. Thymomectomy, which was defined 
as the resection of the thymoma leaving residual thymic tissue, 
was performed in 51 patients (16.7%). Completeness of resec-
tion was observed in 276 patients (90.5%), and R1 resection 
indicating microscopic residual tumor tissue was performed 
in 29 patients (9.5%).
Adjuvant Therapy. Our strategies for adjuvant therapy 
after the initial thymoma resection were as follows: no adju-
vant therapy for stage I thymomas, radiotherapy for invasive 
or incompletely resected thymomas, and chemotherapy (with 
or without radiotherapy) for Masaoka stage IV thymomas. 
However, because these strategies have not been standardized 
for the entire study period, the strategy for adjuvant therapy 
was patient specific according to each surgeon’s preference.
Adjuvant chemotherapy was generally performed 
according to the doxorubicin/cisplatin/vincristine/cyclo-
phosphamide regimen for a total of six cycles every 3 to 4 
weeks and consisted of doxorubicin (40 mg/m2) and cisplatin 
(50 mg/m2) administered intravenously on day 1, vincristine 
(0.6 mg/m2) on day 3, and cyclophosphamide (700 mg/m2) 
on day 4. Other regimens were used, which consisted of 
5-fluorouracil, etoposide and cisplatin, ifosfamide, etopo-
side, and cisplatin.
Radiotherapy was applied at a median dose of 5040 cGy 
(180 cGy/fraction; range, 4500–6300 cGy) for 5 to 6 weeks. 
In case of concurrent chemoradiotherapy, the first three cycles 
of chemotherapy were performed followed by radiotherapy 
and then three further cycles of chemotherapy.
Follow-Up and Recurrence Evaluation
All patients who underwent thymoma resection were 
followed up at the outpatient clinic at 3-month intervals for 
the first year, 6-month intervals for the subsequent year, and 
yearly for the next 3 years. A physical examination and chest 
radiography were carried out on every visit to the outpatient 
clinic. A chest computed tomography (CT) was performed at 
6-month intervals for the first 2 years and at 1-year intervals 
for the subsequent 3 years. However, there was some variation 
in the follow-up policy according to the stage and histology of 
each tumor and the surgeon’s preference, because there was no 
standardized follow-up protocol at our institute.
After 5 years, patients were followed up at our neurology 
or oncology department for any prevailing medical problems. 
The data of nine patients who did not attend follow-up ses-
sions were obtained by direct telephone contact for this study. 
Follow-up for this study is complete up to December 2010.
Statistical Analysis
Descriptive analysis was conducted on clinical features 
of patients, management, and outcomes. Comparative analysis 
to identify differences in patients and tumor characteristics was 
performed using the χ2 test, Fisher’s exact test for categorical 
variables, and Student’s t test for continuous variables. The 
analysis of the survival was conducted using the Kaplan-
Meier method, and the statistical difference was determined 
using the log-rank test. Cox proportional hazards model was 
used for multivariate analyses of prognostic factors. The 
survival period after recurrence was calculated from the date 
of recurrence diagnosis to the date of the last follow-up or of 
death. The survival period after initial resection was calculated 
from the date of resection of initial thymoma to the date of 
the last follow-up or of death. A p value less than 0.05 was 
FIGURE 1.  Diagram of the study. WHO, World Health 
Organization.
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considered statistically significant. All statistical analysis was 
performed using SPSS version 18.0 for Windows (Statistical 
Package for Social Science, SPSS Inc., Chicago, IL).
RESULTS
Clinical Features
At the time of recurrent thymoma presentation, five 
patients were symptomatic; they had chest pain, facial swell-
ing, palpable neck mass, dizziness/palpitations, and cough/
chest discomfort, respectively. In 36 patients who were asymp-
tomatic, the first tool of detection for recurrent thymoma was 
chest roentgenogram in one patient, neck sonogram in one 
patient, and chest CT in 34 patients.
The median disease-free interval, the interval from the 
initial resection to recurrence, was 52 months (range, 6–234 
months). The median follow-up time after recurrence was 
25 months (range, 2–134 months), and the median follow-
up time after initial resection was 92 months (range, 2–241 
months). Eleven patients had local recurrence, 29 had regional 
recurrence, seven had distant recurrence (four lung, one liver, 
and one abdominal lymph node metastasis), and six had over-
lapped recurrence (Fig. 2). Regarding the median intervals 
from the initial resection to recurrence, there was no defi-
nite association with WHO histologic type and stage; how-
ever, higher stage tumors had a tendency to earlier recurrence 
(Fig. 3). The clinical features of patients are shown in Table 1.
Re-Resection of Recurrent Thymoma
Re-resection was performed by thoracotomy in 13 
patients, by median sternotomy in one, and by video-assisted 
thoracic surgery in one patient. Mediastinal recurrent thymoma 
resections occurred in two patients, pleural metastasectomies 
in 11, both mediastinal resection and pleural metastasectomy 
in one, and pulmonary metastasectomy in one. Complete 
 re-resection was achieved in 13 patients (87%), and micro-
scopic incomplete resection was found in two patients with 
pleural metastasis. The second recurrence after resection of 
recurrent thymoma occurred in three patients. They all had 
pleural recurrences. Two of them underwent a third resection.
There was no postoperative 30-day mortality or in-
hospital mortality after re-resection. There were three minor 
morbidities: one chylothorax and two prolonged drainage 
cases that lasted more than 7days. During adjuvant chemo-
therapy after re-resection, two patients died of pancytopenia. 
Management and outcomes of the patients who underwent re-
resection for recurrent thymoma are outlined in Table 2.
FIGURE 2. The patterns of recurrence.
FIGURE 3. Median intervals from the initial resection to 
recurrence according to WHO histological type and Masaoka 
stage. WHO, World Health Organization.
TABLE 1.  Clinical Features of 41 Patients Who had 
Recurrence After Resection of Thymoma
Variables Number Recurrent Rate (%)
Disease free interval, median (mo) — 52.0 (6–234)
Follow-up after recurrence, median — 25.0 (2–134)
Follow-up after initial resection, median — 92.0 (12–241)
Median age, years (range)
 At initial tumor resection — 41.0 (25–72)
 At recurrence — 47.9 (28–76)
Sex
 Female 20 —
 Male 21 —
Myasthenia gravis
 Yes 22 —
 No 19 —
WHO histologic type of initial tumora
 A 0/19 0.0
 AB 4/63 6.3
 B1 2/48 4.2
 B2 11/59 18.6
 B3 24/116 20.7
Masaoka stage of initial tumora
 I 8/132 6.0
 II 13/114 11.4
 III 11/41 26.8
 IVa 7/14 50.0
 IVb 2/4 50.0
Pattern of recurrence (overlap)
 Local 11 —
 Regional 29 —
 Distant 7 —
Treatment of recurrence
 None 9 —
 Resection only 4 —
 Resection/radiotherapy 4 —
 Resection/chemotherapy 5 —
 Resection/CCRTxb 2 —
 Chemotherapy only 11 —
 CCRTxb 5 —
 Other 1 —
WHO, World Health Organization; CCRT
X
, concurrent chemoradiotherapy.
aThe number and percent mean that the portion of 305 patients who underwent 
resection of thymoma with curative intent. For example, in cases of type AB, four of 63 
patients had recurrence. Thus, recurrence rate of type AB thymoma is 6.3%. 
bConcurrent chemoradiotherapy.
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Nonsurgical Management of Recurrent 
Thymoma
Of 26 patients who did not undergo resection of recur-
rent thymoma, 11 patients received chemotherapy, five patients 
received concurrent chemoradiotherapy, one patient received 
ethanol injection therapy in a metastatic cervical lymph node, 
and the remaining nine patients did not receive any treatment. 
Of 26 patients, eight patients were confirmed recurrence by 
tumor biopsy; however, the remaining 18 patients were diag-
nosed only by image studies.
Among 26 patients who did not receive surgical re-resec-
tion were 17 patients who had pleural recurrence (one local 
and 16 regional). The reasons for not performing re-resection 
were as follows: five patients had inoperable extensive unilat-
eral lesions, three had bilateral lesions, two underwent follow-
up by having their image files observed, two patients refused 
treatment, one patient was in a poor condition as a result of 
liver cirrhosis, one because of unknown reason, one patient 
did not refer to surgeon, and two patients had stage IV initial 
thymomas despite resectable lesions.
The remaining 11 patients had local or distant recur-
rence because of the following reasons: three had extratho-
racic lesions, three had bilateral multiple pulmonary lesion, 
two had cervical lymph nodes. The follow-ups of two patients 
were carried out by observation of image files, and one patients 
refused. In four cases of pulmonary recurrence, one patient 
with a single lesion received re-resection, but three patients 
with bilateral multiple lesions received chemotherapy.
There was no treatment-related death or myasthenia 
gravis-related death. Among 16 patients who received 
chemotherapy or chemoradiotherapy, four had life-threatening 
adverse events according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events version 
4.0 (Common Terminology Criteria for Adverse Events 
grade 4)17 (four decreased white cell count), three patients had 
medically significant adverse events (Common Terminology 
Criteria for Adverse Events grade 3) (one febrile netropenia, 
one lung infection, and one platelet count decreased), and five 
patients had adverse event of grade 2 (peripheral neuropathy, 
anemia, rash pustular, nausea, and dispepsia). Management 
and outcomes of the patients who underwent re-resection for 
recurrent thymoma are outlined in Table 3.
Survival
Of 41 patients with recurrent thymoma, 14 died of 
recurrent-thymoma–related cause, two died of treatment-
related cause, and one died of liver cirrhosis. Twenty-one 
patients were alive with stable disease status or no evidence of 
disease, and the remaining three patients were alive with dis-
ease progression despite management of recurrent thymoma 
(Tables 2 and 3). Overall 5-year and 10-year survival rates 
after recurrence were 59.7% and 33.2%, respectively (Fig. 4).
Prognosis After Recurrence
WHO histological type A, AB, and B1 tumors had better 
survival than B2 and B3 tumors. In addition, the patients who 
underwent complete re-resection had better survival than 
the patients who did not. According to the interval and the 
pattern of recurrence, the survival graph showed a tendency 
toward difference even though the p value was not below the 
level of statistical significance. That is, the patients who had 
recurrence after 5 years had better survival than those who 
had recurrence within 5 years, and the patients with local 
recurrence had better survival than the patients with regional 
or distant recurrence. There was no significant difference in 
survival according to the presence of myasthenia gravis and 
the Masaoka stage of the initial tumor (Fig. 5). In multivariate 
analysis, we were unable to find any independent predictor of 
survival for recurrent thymoma (Table 4).
Complete Re-Resection Versus Non/Incomplete 
Re-Resection
Between the patients who underwent complete resection 
of recurrent thymoma and the patients who received nonsurgi-
cal management or incomplete resection, there was no statisti-
cal difference regarding the pattern of recurrence, recurrence 
free interval, WHO histologic type, and Masaoka stage of 
initial thymoma (p values: 0.550, 0.742, 0.084, and 0.173, 
respectively). Regarding survival after recurrence, ther com-
plete re-resection groups had significantly better survival than 
the non/incomplete re-resection group (5-year survival rate: 
90.9% versus 44.7%, p = 0.014) (Fig. 5F). Regarding survival 
after initial resection of thymoma, the complete re-resection 
group had comparable survival to the patients without recur-
rence (5, 10, and 15-year survival: 91.7%, 91.7%, and 91.7% 
versus 90.7%, 86.5%, and 82.7%, p = 0.618), and significant 
better survival in comparison with non/incomplete re-resec-
tion group (5, 10, and 15-year survival: 91.7%, 91.7%, and 
91.7% versus 81.6%, 56.7%, and 34.0%, p = 0.018) (Fig. 6).
DISCUSSION
In this study on the management of recurrent thymoma, 
we found that WHO histological type AB or B1 and complete 
re-resection are positive prognostic factors for survival after 
recurrence. We also found that the patients who underwent 
complete re-resection have an excellent prognosis; their sur-
vival after initial thymoma resection is comparable to that of 
patients without recurrence, and their survival after recur-
rence is much better than in those patients who did not receive 
complete re-resection of recurrent thymoma.
Even though there are not many reports on the man-
agement of recurrent thymoma, there is some consensus that 
complete re-resection is recommended. The better survival 
of the complete re-resection group has been reported not 
only after recurrence,5,6,8,18,19 but also after initial thymoma 
resection.20
However, it is necessary to consider incomplete resec-
tion. According to the report of Haniuda et al.7 the four patients 
receiving complete resection were alive 48 months after sur-
gery. The remaining 11 patients underwent only a subtotal 
resection and had disappointing outcomes. Thus, re-resection 
had no beneficial effect on postrecurrent survival.
In our study, we were able to achieve complete re- 
resection in 13 (87%) of 15 patients who underwent re- 
resection, and a second recurrence was observed in only 3 
(23%) of 13 patients who underwent complete re-resection. 
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In addition, 11 patients (85%) are presently alive with no 
evidence of disease. However, two patients who under-
went incomplete re-resection of recurrent thymoma showed 
disappointing outcomes. One patient who had huge pleu-
ral implants infiltrating the diaphragm underwent radical 
resection with curative intent; however, microscopic review 
revealed incomplete resection of margin, and the patient 
died of pneumonia after postoperative chemotherapy 3 
months after re-resection. Another patient who had multiple 
pleural implants could not achieve complete resection of all 
pleural lesions, and the patient died of progression of dis-
ease 25 months after re-resection. The survival periods of 
these two patients who underwent incomplete re-resection 
were lower than the median survival period of 31 months 
of patients who did not receive re-resection for recurrent 
thymoma.
On the basis of those results, we can conclude that re-
resection is the optimal treatment of recurrent thymoma when 
complete resection is possible. Therefore, long-term surveil-
lance and careful follow-up are essential for early detection of 
recurrence to increase the chance of complete re-resection of 
recurrent thymoma.
In our study, the median interval from initial thymoma 
resection to recurrence was 52 months, and six (15%) of 
41 patients had recurrence after more than 10 years of initial 
thymoma resection. Thus, lifetime surveillance extended to at 
least 20 years is necessary.
In addition, 36 (88%) of 41 patients with recurrence 
were asymptomatic at the time of presentation of recurrent 
thymoma, and 34 of those 36 asymptomatic patients were 
diagnosed with recurrence by chest CT. Thus, we are of 
the opinion that chest CT can be the best tool for surveillance 
after thymoma resection; an annual chest CT within 5 years 
after thymoma resection and biannual chest CTs after 5 years 
for at least 20 years are recommended.
As to the number of recurrent lesions, Margaritora et 
al.8 found that single lesions showed better prognosis than 
multiple lesions (5-year survival rate; 100% versus 64%). 
Lucchi et al.21 also reported that single pleural recurrence had 
significantly better prognosis than multiple pleural recurrence. 
TABLE 2.  Clinical Features and Outcomes of Patients Who Underwent Re-resection for Recurrent Thymoma
N
Sex/
Age MG
Initial Tumor
Treatment After 
Initial Resection
Recurrent Tumor
DFI (m)
Approach for 
Surgery
Complete 
Re-resection
Treatment After 
Re-resection
Recurrence After 
Re-resection
Treatment of 
Re-recurrence Current Status
Survival 
Time (m)Stage/Histology Site/Histology
1 F/38 ±a IVa B2 + B3 None Regional B2 + B3 10 Left thoracotomy Yes None
Pleural recurrence 
after 58 months
CTxb Alive, PD (liver metastasis) 63
2 M/32 + III B2 + B3
CCRTx (ADOC#6, 
5400 cGy)
Regional B2 + B3 24 Left VATS Yes None — — Alive, NED 55
3 M/44 + IIb B2 + B3
CCRTx (ADOC#6, 
4500 cGy)
Regional B3 27 Right thoracotomy Yes None
Pleural recurrence 
after 13 months
Resection/ 
CCRTxc
Alive, NED 71
4 M/36 + III B3 RTx (5940 cGy) Regional B3 32 Left thoracotomy No CTx (ADOC#1)
Treatment-related death 
(pneumonia/pancytopenia)
3
5 F/29 + III B2 + B3 RTx (5940 cGy) Regional B3 32 Left thoracotomy Yes CTx (ADOC#5) — —
Treatment-related death 
(hepatitis/pancytopenia)
7
6 F/25 + III B2 RTx (5040 cGy) Regional B2 33 Right thoracotomy Yes RTx (5400 cGy) — — Alive, NED 4
7 F/45 − III B3 None Regional B3 40 Right thoracotomy Yes RTx (4500 cGy)
Pleura recurrence 
After 64 
months
Resection/ 
RTxd
Alive, NED 75
8 M/39 − I B2 + B3 None Regional B2 + B3 52 Left thoracotomy Yes
CCRTx 
(ADOC#6, 
4500 cGy)
— — Alive, NED 35
9 F/45 + I B2 None Local B2 71 Right thoracotomy Yes RTx (5400 cGy) — — Alive, NED 42
10 F/36 + IIa B2 RTx (4500 cGy) Local B2 + B3 73 Left thoracotomy Yes
CCRTx 
(ADOC#6, 
4500 cGy)
— — Alive, NED 103
11 M/41 − IIb B3 RTx (4500 cGy) Regional B3 83 Right thoracotomy Yes CTx (ADOC#4) — — Alive, NED 110
12 M/27 ±e I B2 None Local regional B2 96
Median 
sternotomy
Yes RTx (5000 cGy) — — Alive, NED 17
13 M/43 ±e IIb B1 RTx (4500 cGy) Regional B1 120 Left thoracotomy No CTx (ADOC#1) — — Tumor-related death 25
14 M/47 − III B3 RTx (5400 cGy) Distant (lung) B3 151 Right thoracotomy Yes None — — Alive, NED 6
15 F/42 + III B2 None Regional B3 178 Right thoracotomy Yes CTx (ADOC#4) — — Alive, NED 29
ADOC, doxorubicin/cisplatin/vincristine/cyclophosphamide; CCRTx, concurrent chemoradiotherapy; CR, complete response of treatment; CTx, chemotherapy;  
DFI, disease-free interval; MG, myasthenia gravis; NED, no evidence of disease; PD, progression of disease; RTx, radiotherapy; SD, stable status of disease;  
VATS, video-assisted thoracoscopic surgery.
aPost re-resection MG; diagnosis of MG after re-resection of recurrent thymoma.
bPaclitaxel/cisplatin.
cPleural metastasectomy under right thoracotomy + paclitaxel/ifosfamide #5/radiotherapy (5490 cGy).
dPleural metastasectomy under right thoracotomy + radiotherapy (4600 cGy).
ePost-thymectomy MG; diagnosis of MG after resection of initial thymoma.
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TABLE 2.  Clinical Features and Outcomes of Patients Who Underwent Re-resection for Recurrent Thymoma
N
Sex/
Age MG
Initial Tumor
Treatment After 
Initial Resection
Recurrent Tumor
DFI (m)
Approach for 
Surgery
Complete 
Re-resection
Treatment After 
Re-resection
Recurrence After 
Re-resection
Treatment of 
Re-recurrence Current Status
Survival 
Time (m)Stage/Histology Site/Histology
1 F/38 ±a IVa B2 + B3 None Regional B2 + B3 10 Left thoracotomy Yes None
Pleural recurrence 
after 58 months
CTxb Alive, PD (liver metastasis) 63
2 M/32 + III B2 + B3
CCRTx (ADOC#6, 
5400 cGy)
Regional B2 + B3 24 Left VATS Yes None — — Alive, NED 55
3 M/44 + IIb B2 + B3
CCRTx (ADOC#6, 
4500 cGy)
Regional B3 27 Right thoracotomy Yes None
Pleural recurrence 
after 13 months
Resection/ 
CCRTxc
Alive, NED 71
4 M/36 + III B3 RTx (5940 cGy) Regional B3 32 Left thoracotomy No CTx (ADOC#1)
Treatment-related death 
(pneumonia/pancytopenia)
3
5 F/29 + III B2 + B3 RTx (5940 cGy) Regional B3 32 Left thoracotomy Yes CTx (ADOC#5) — —
Treatment-related death 
(hepatitis/pancytopenia)
7
6 F/25 + III B2 RTx (5040 cGy) Regional B2 33 Right thoracotomy Yes RTx (5400 cGy) — — Alive, NED 4
7 F/45 − III B3 None Regional B3 40 Right thoracotomy Yes RTx (4500 cGy)
Pleura recurrence 
After 64 
months
Resection/ 
RTxd
Alive, NED 75
8 M/39 − I B2 + B3 None Regional B2 + B3 52 Left thoracotomy Yes
CCRTx 
(ADOC#6, 
4500 cGy)
— — Alive, NED 35
9 F/45 + I B2 None Local B2 71 Right thoracotomy Yes RTx (5400 cGy) — — Alive, NED 42
10 F/36 + IIa B2 RTx (4500 cGy) Local B2 + B3 73 Left thoracotomy Yes
CCRTx 
(ADOC#6, 
4500 cGy)
— — Alive, NED 103
11 M/41 − IIb B3 RTx (4500 cGy) Regional B3 83 Right thoracotomy Yes CTx (ADOC#4) — — Alive, NED 110
12 M/27 ±e I B2 None Local regional B2 96
Median 
sternotomy
Yes RTx (5000 cGy) — — Alive, NED 17
13 M/43 ±e IIb B1 RTx (4500 cGy) Regional B1 120 Left thoracotomy No CTx (ADOC#1) — — Tumor-related death 25
14 M/47 − III B3 RTx (5400 cGy) Distant (lung) B3 151 Right thoracotomy Yes None — — Alive, NED 6
15 F/42 + III B2 None Regional B3 178 Right thoracotomy Yes CTx (ADOC#4) — — Alive, NED 29
ADOC, doxorubicin/cisplatin/vincristine/cyclophosphamide; CCRTx, concurrent chemoradiotherapy; CR, complete response of treatment; CTx, chemotherapy;  
DFI, disease-free interval; MG, myasthenia gravis; NED, no evidence of disease; PD, progression of disease; RTx, radiotherapy; SD, stable status of disease;  
VATS, video-assisted thoracoscopic surgery.
aPost re-resection MG; diagnosis of MG after re-resection of recurrent thymoma.
bPaclitaxel/cisplatin.
cPleural metastasectomy under right thoracotomy + paclitaxel/ifosfamide #5/radiotherapy (5490 cGy).
dPleural metastasectomy under right thoracotomy + radiotherapy (4600 cGy).
ePost-thymectomy MG; diagnosis of MG after resection of initial thymoma.
In our study, there was no difference in the 5-year survival rate 
between nine patients with single lesions and 32 patients with 
multiple lesions (71.1% versus 56.5%, p = 0.442). When only 
the patients with regional recurrence were compared, there was 
also no difference between two patients with single lesions 
and 26 patients with multiple lesions (50% versus 54.4%, 
p = 0.776). On the basis of those results, we inferred that com-
plete resection is more important as a prognostic determinant 
than the number of recurrent lesions.
The role of adjuvant therapy after re-resection of 
recurrent thymoma is still difficult to determine. Eleven of 
15 patients who underwent re-resection of recurrent thy-
moma received adjuvant therapy after re-resection. However, 
because the strategy of adjuvant therapy was not uniform, it is 
difficult to interpret its effectiveness. Nevertheless, adjuvant 
therapy after re-resection seems to have an important role in 
the management for regional recurrence of thymoma.
In our study, 29 (71%) of 41 patients with recurrence 
presented with regional recurrence. Of the patients with 
regional recurrence, 12 patients underwent re-resection, and 
17 patients received nonsurgical management. Of 10 patients 
who achieved complete re-resection, seven received adjuvant 
therapy after complete re-resection, and three did not receive 
any adjuvant therapy. Of the three patients who received only 
re-resection, two patients had a second pleural recurrence. 
Therefore, in the case of regional recurrence, adjuvant therapy 
after re-resection might be needed.
A second recurrence after re-resection of recurrent thy-
moma occurred in three (20%) of 15 patients who underwent 
re-resection. Of those three patients, two underwent a third 
resection and are alive with no evidence of disease status at 
present. The other patient, who could not undergo a third 
resection, is alive; however, she has progression of disease. As 
found by our study, Regnard et al.5 reported that 16% (three of 
19 patients with complete resection) had a second recurrence; 
one of those patients who had a third resection was still alive 
at follow-up, and two patients who did not undergo a third 
resection died of tumor growth. Therefore, if complete resec-
tion is possible, a third resection can achieve a better progno-
sis, even after a second recurrence.
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TABLE 3.  Clinical Features and Outcomes of Patients Who Received Nonsurgical Management for Recurrent Thymoma
N
Sex/
Age MG
Initial Tumor
Treatment After 
Initial Resection
Recurrent tumor
DFI 
(m)
Treatment of 
Re-recurrence
Current 
Status
Survival 
Time (m)Stage/Histology Site/Histology
1 M/34 − III B3 RTx (6000 cGy) Regional Unknown 6 Follow-up Alive, SD 6
2 F/32 + IIb B2 + B3 CCRTx (ADOC#4, 
4500 cGy)
Regional Unknown 45 Follow-up Alive, SD 6
3 M/37 − I B2 None Regional Unknown 87 Follow-up Alive, SD 27
4 M/30 + I B2 None Local Unknown 148 Follow-up Alive, SD 8
5 F/46 − IVb B3 RTx (6000 cGy) Local / 
Regional
Unknown 10 None Tumor-related 
death, PD
2
6 M/64 − IIa AB RTx (5400 cGy) Regional Unknown 20 None Tumor-related 
death
119
7 F/63 − IVa B3 CCRTx (ADOC#6, 
5040 cGy)
Regional Unknown 41 None Non-tumor–
related 
death (liver 
cirrhosis)
27
8 M/32 + I B2 + B3 None Regional B3 65 None Tumor-related 
death
2
9 F/30 + IIa AB RTx (4500 cGy) Regional Unknown 82 None Tumor-related 
death
2
10 F/44 + IVb B3 CCRTx (ADOC#6, 
5040 cGy)
Distant (lung) Unknown 10 Chemotherapy 
(paclitaxel/
ifosfamide #6 
+ etoposide/
cisplatin #1)
Alive, PD 55
11 F/50 − III B1 RTx (4500 cGy) Regional Unknown 16 Chemotherapy 
(ADOC #5)
Tumor-related 
death
10
12 F/47 − IVa B2 RTx (4500 cGy) Regional Unknown 30 Chemotherapy 
(ADOC #1)
Tumor-related 
death
2
13 F/63 + III AB RTx (4500 cGy) Regional AB 31 Chemotherapy 
(ADOC #7 + 
vincristine/if-
osphamide #4)
Tumor-related 
death
31
14 F/48 + IIb B3 None Distant (liver) Unknown 51 Chemotherapy 
(cisplatin #6)
Tumor-related 
death
19
15 M/31 − IVa B3 CCRTx ADOC#6, 
5400 cGy)
Local (pleura) Unknown 52 Chemotherapy 
(etoposide/
cisplatin #6)
Alive, SD 24
16 M/51 − IVa B2 CCRTx (ADOC#6, 
4500 cGy)
Regional /  
distant (lung)
Unknown 59 Chemotherapy 
(ADOC #3 + 
paclitaxel/ifos-
phamide #1)
Tumor-related 
death
103
17 F/52 − IIa AB RTx (5000 cGy) Local/regional Unknown 67 Chemotherapy 
(ADOC #6)
Tumor-related 
death
13
18 F/41 − IVa B3 RTx (5500 cGy) Regional Unknown 73 Chemotherapy 
(ADOC #3)
Alive, SD 130
19 F/40 − I B2 None Regional B2 114 Chemotherapy 
(paclitaxel/
cisplatin #6)
Alive, SD 6
20 M/32 + I B3 None Local/distant 
(lung)
B2 + B3 234 Chemotherapy 
(ADOC #2)
Tumor-related 
death
6
21 M/59 − IIa B3 RTx (5400 cGy) Distant (liver) B3 15 CCRTx (doxo-
rubicin/carbo-
platin #2, 4440 
cGy)
Tumor-related 
death
18
22 M/49 + IIb B3 CTx (ADOC#6), Local/regional Unknown 36 CCRTx (pacli-
taxel/ifospha-
mide #2 + 
ifosphamide 
mono #6, 4500 
cGy)
Alive, PD 55
23 M/35 + IIb B2 + B3 RTx (5040 cGy) Distant  
(abdominal 
LN)
B2 + B3 45 CCRTx (ADOC 
#6, 5940 cGy)
Alive, CR 59
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As to the prognosis of recurrent thymoma, several prog-
nostic factors have been determined. Complete re-resection 
and local recurrence were known as a positive prognostic fac-
tors,6 and early recurrence (<40 months) was known as a neg-
ative prognostic factor.4 In our study, complete re- resection 
was also a positive predictive factor, as previously mentioned. 
Local recurrence and late recurrence (≥5 years) were associ-
ated with positive prognosis despite their statistical insignifi-
cance. In addition, WHO histological type of AB or B1 was a 
positive prognostic factor.
In our study, WHO type was also associated with recur-
rence pattern; WHO types of the patients who had distant 
recurrence were all type B2 or B3. In terms of other relevance 
between the WHO type and recurrence, Okumura et al.20 
reported that as the WHO type is higher, the average interval 
from the initial resection to recurrence is shorter. However, 
our study did not show that kind of pattern. Instead we found 
that as the Masaoka stage becomes higher, the interval from 
initial resection to recurrence seems to get shorter. Those 
results are similar to the previously reported results; the mean 
time to recurrence was 10 years in patients with a stage I thy-
moma compared with 3 years in patients with a stage II to IV 
thymoma.22
Regarding the WHO histological type of recurrent thy-
moma, there have been reports that the histology can change 
from a primary tumor to a recurrent tumor, and this occurs 
in the direction of aggressive histological types.4,23 In our 
patients, the change of histological type was presented in six 
patients; type B2+B3 to B3 was confirmed in three patients, 
type B2 to B2+B3 in one patient, type B2 to B3 in one patient 
and type B3 to B2+B3 in one patient. In five cases except 
the last case, the histological types were changed to histo-
logically more aggressive types. Thus, we confirmed that the 
trend in histological change occurred in the direction of more 
aggressive histological types. In the context of histological 
changes of recurrent thymoma, we should consider the effect 
of steroids. Tateyama et al.24 reported histological changes 
of thymoma after corticosterioid treatment; they found that 
the tumors changed to predominantly epithelial-type thymo-
mas after the treatment. In our study, 11 of 22 patients with 
myasthenia gravis received steroid therapy between resection 
of initial thymoma and recurrence. The histological type of 
recurrent thymoma was confirmed in nine of these patients. 
Among these nine patients were four patients presenting with 
histological change; one from type B2(80%)+B3(20%) to type 
B3, one from type B2 to B2(50%)+B3(50%), one from type 
B2 to type B3, and one from type B3 to type B2+B3. As many 
as 44% (four of nine) of patients who received steroid therapy 
presented with histological changes. Thus, we think that ste-
roids can affect histological types of thymomas; the change of 
histological types is attributable to the reduction of lympho-
cytes and the subsequent emphasis of epithelial components 
after steroid therapy. As a result, the histological types change 
to predominantly epithelial types as the report of Tateyama et 
al.24 Our hypothesis can be supported by the fact that there is 
not any change from type A, AB, B1 to type B2 or B3. Further 
studies are warranted to confirm the effect of steroids.
In the management of stage IVb thymoma, surgery is 
generally not applicable. Radiotherapy or chemotherapy is an 
appropriate option,10 even though generic recommendations 
of management are not applicable because stage IVb thymo-
mas are extremely rare. Our two cases with stage IVb of initial 
thymoma also determined lymph node metastasis after resec-
tion. One showed metastasis to the pretracheal lymph nodes, 
and another showed metastasis to the subaortic and left upper 
lobar lymph nodes. These two patients showed recurrence 
quickly after resection. Therefore, thorough preoperative eval-
uation should be done to avoid inappropriate resection.
There are some limitations in our study. First, this 
study is a retrospective single-center study covering a long 
time period, over which the operational approach, treatment 
modality, chemotherapy regimen, and follow-up policy were 
not uniform. The study may have intrinsic bias; however, those 
are the limits of all studies concerning thymoma. Second, 
we were unable to assess the outcomes of each nonsurgical 
24 M/38 − IVa B2 RTx (5000 cGy) Regional Unknown 83 CCRTx (ADOC 
#2, 4600 cGy)
Tumor-related 
death
134
25 F/36 + III B3 RTx (4000 cGy) Local (cervical 
node)
B3 222 CCRTx (ADOC 
#3, 6000 cGy)
Alive, CR 12
26 M/72 − IIb B3 RTx (4000 cGy) Local (cervical 
node)
B3 52 Ethanol injection Alive, CR 43
ADOC, doxorubicin/cisplatin/vincristine/cyclophosphamide; CCRTx, concurrent chemoradiotherapy; CR, complete response of treatment; CTx, chemotherapy; DFI, disease-free 
interval; MG, myasthenia gravis; PD, progression of disease; RTx, radiotherapy; SD, stable status of disease.
FIGURE 4. Overall survival after recurrence of patients with 
recurrent thymoma.
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FIGURE 5.  Overall survival difference after recurrence according to the presence of myasthenia gravis (A), WHO histological 
type (B), Masaoka stage of the initial thymoma (C), interval from the initial resection to recurrence (D), pattern of recurrence (E), 
and completeness of re-resection (F).
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management, such as chemotherapy or chemoradiotherapy, 
because our study had a small number of subjects undergo-
ing each management modality. Third, our follow-up method 
5 years after thymoma resection was not appropriate to con-
firm recurrence. Nine patients who were followed up by phone 
were regarded as having no recurrence; however, because we 
were not able to check their medical status, they might have 
had recurrences. Therefore, our recurrence rate may be under-
estimated. Despite these limitations, our study has signifi-
cance in that this is one of the few reports about management 
of recurrent thymoma. Multicenter cooperative group clini-
cal trials are required to assess the management for recurrent 
thymoma.
In conclusion, in our study, we have shown that the 
favorable prognostic factors of recurrent thymoma were WHO 
histologic types AB or B1 and complete re-resection. In par-
ticular, complete re-resection of recurrent thymoma contrib-
utes to better survival compared to other types of management.
Therefore, we suggest that re-resection of recurrent 
thymomas may be the optimal approach of management if 
complete resection is possible, and long-term surveillance 
extended for at least 20 years may be essential for early detec-
tion of recurrence to increase the chance of the complete 
 re-resection of recurrent thymoma.
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